A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma

Background: Mipsagargin (G-202) is a thapsigargin-based prodrug with cytotoxic activity masked by a peptide that is cleaved by prostate-specific membrane antigen (PSMA), a protease expressed in prostate cancer cells and the endothelium of tumor vasculature. It was hypothesized that PSMA-mediated act...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingam, Devalingam, Peguero, Julio, Cen, Putao, Arora, Sukeshi P., Sarantopoulos, John, Rowe, Julie, Allgood, Victoria, Tubb, Benjamin, Campos, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
https://www.ncbi.nlm.nih.gov/pubmed/31212948
http://dx.doi.org/10.3390/cancers11060833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627768/
https://www.ncbi.nlm.nih.gov/pubmed/31212948
http://dx.doi.org/10.3390/cancers11060833

Ejemplares similares